Floatz logo

Raloxifene

Brain Tumor

The University of Texas Health Science Center at San AntonioSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

61 Active assets in the Brain Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Vorinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Raloxifene is also rated in:

schizophreniform disorderDormant
A
Indicative ·
83 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →